GLP-1 Drugs Show Surprising Efficacy in Treatment-Resistant Depression Trials

Two independent Phase 2 trials have reported that GLP-1 receptor agonists — the drug class that includes semaglutide and tirzepatide — produce clinically meaningful reductions in depression scores in patients with treatment-resistant major depressive disorder. The results, published simultaneously in JAMA Psychiatry and The Lancet, are the strongest evidence yet that the metabolic drugs have meaningful effects on the brain.

The Results

Both trials enrolled patients with MDD who had failed at least two prior antidepressant regimens. After 16 weeks, patients randomized to GLP-1 therapy showed significantly greater improvement on the MADRS and PHQ-9 scales than those on placebo. Roughly 45% of treated patients met response criteria, compared with 22% on placebo. The effect sizes were comparable to those seen with esketamine, one of the few recent advances in treatment-resistant depression.

"We did not expect this effect size. The reduction in depressive symptoms was clinically significant and appeared within the first four weeks," said Dr. Rebecca Brachman, who led the JAMA Psychiatry trial at NYU.

Why Might It Work?

The mechanism remains a puzzle. GLP-1 receptors are expressed in brain regions involved in mood regulation, including the ventral tegmental area and the hippocampus. The drugs also reduce systemic inflammation, which has been linked to depressive symptoms. Animal studies suggest direct effects on dopamine signaling.

• Trial 1: NYU, semaglutide, 220 patients
• Trial 2: King's College London, tirzepatide, 280 patients
• Response rate: 45% (drug) vs 22% (placebo)
• Adverse events: GI side effects consistent with prior GLP-1 data

What Comes Next

Both sponsors have announced Phase 3 trials that will enroll several thousand patients across multiple sites. If the results hold, the implications are substantial: an existing, generic-capable drug class with broad insurance coverage could become a first-line option for treatment-resistant depression. Manufacturers including Novo Nordisk and Eli Lilly have signaled intent to pursue depression as an additional indication.

Researchers caution that the Phase 2 results, however striking, will need to be replicated at scale. The history of psychiatry is littered with early findings that did not survive larger trials. But the consistency of the signal across two independent trials — and the size of the effect — has raised cautious optimism among clinicians who have run out of good options for their most difficult patients.